293 related articles for article (PubMed ID: 33560081)
21. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation.
Chaftari AM; Hachem RY; Ramos E; Kassis C; Campo M; Jiang Y; Prince RA; Wang W; Raad II
Transplantation; 2012 Aug; 94(3):302-8. PubMed ID: 22814329
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia.
Mattiuzzi G; Yilmaz M; Kantarjian H; Borthakur G; Konopleva M; Jabbour E; Brown Y; Pierce S; Cortes J
J Infect Chemother; 2015 Sep; 21(9):663-7. PubMed ID: 26141814
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Network Meta-analysis.
Wang J; Zhou M; Xu JY; Zhou RF; Chen B; Wan Y
JAMA Netw Open; 2020 Oct; 3(10):e2017652. PubMed ID: 33030550
[TBL] [Abstract][Full Text] [Related]
24. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
[TBL] [Abstract][Full Text] [Related]
25. Breakthrough invasive fungal infection in patients with myeloid malignancy receiving posaconazole tablet prophylaxis: Clinical features, risk factors, and posaconazole profiles.
Hong JY; Kang CI; Yang J; Ko JH; Huh K; Cho SY; Chung DR; Jung CW; Peck KR
Med Mycol; 2023 Apr; 61(5):. PubMed ID: 37120735
[TBL] [Abstract][Full Text] [Related]
26. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
[TBL] [Abstract][Full Text] [Related]
27. Impact of fluconazole versus posaconazole prophylaxis on the incidence of fungal infections in patients receiving induction chemotherapy for acute myeloid leukemia.
Devanlay C; Tavernier-Tardy E; Bourmaud A; Falk AT; Raberin H; Menguy S; Guyotat D; Magné N; Cornillon J
Biomed J; 2015; 38(3):235-43. PubMed ID: 25355388
[TBL] [Abstract][Full Text] [Related]
28. Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
Dahlén T; Kalin M; Cederlund K; Nordlander A; Björkholm M; Ljungman P; Blennow O
Eur J Haematol; 2016 Feb; 96(2):175-80. PubMed ID: 25880378
[TBL] [Abstract][Full Text] [Related]
29. Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia.
Wasylyshyn A; Linder KA; Castillo CG; Zhou S; Kauffman CA; Miceli MH
Mycopathologia; 2020 Apr; 185(2):299-306. PubMed ID: 31939052
[TBL] [Abstract][Full Text] [Related]
30. Management of Invasive Fungal Infections in Pediatric Acute Leukemia and the Appropriate Time for Restarting Chemotherapy.
Tüfekçi Ö; Yılmaz Bengoa Ş; Demir Yenigürbüz F; Şimşek E; Karapınar TH; İrken G; Ören H
Turk J Haematol; 2015 Dec; 32(4):329-37. PubMed ID: 25913290
[TBL] [Abstract][Full Text] [Related]
31. Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis: A single-center, observational, case-control study in South Korea.
Yang E; Choi EJ; Park HS; Lee SO; Choi SH; Kim YS; Lee JH; Lee JH; Lee KH; Kim SH
Medicine (Baltimore); 2021 May; 100(20):e25448. PubMed ID: 34011022
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of anti-fungal but not anti-bacterial prophylaxis in intensive primary AML therapy: a real-world, retrospective comparative single-centre study.
Gerber B; Köppel J; Paul M; Nguyen-Kim TD; Frauenfelder T; Nair G; Schanz U; Manz MG
Swiss Med Wkly; 2014; 144():w13985. PubMed ID: 25055166
[TBL] [Abstract][Full Text] [Related]
33. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
Ullmann AJ; Lipton JH; Vesole DH; Chandrasekar P; Langston A; Tarantolo SR; Greinix H; Morais de Azevedo W; Reddy V; Boparai N; Pedicone L; Patino H; Durrant S
N Engl J Med; 2007 Jan; 356(4):335-47. PubMed ID: 17251530
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
Krishna G; AbuTarif M; Xuan F; Martinho M; Angulo D; Cornely OA
Pharmacotherapy; 2008 Oct; 28(10):1223-32. PubMed ID: 18823218
[TBL] [Abstract][Full Text] [Related]
35. Real-world effectiveness of antifungal prophylaxis with posaconazole as the primary agent in patients with haematological malignancies.
Strand AM; Alexander BD; Sarpong E; Wong JR; Engemann A; Rizzieri D; Wu Y; Johnson MD
Mycoses; 2022 Nov; 65(11):1050-1060. PubMed ID: 35816393
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry.
Pagano L; Caira M; Candoni A; Aversa F; Castagnola C; Caramatti C; Cattaneo C; Delia M; De Paolis MR; Di Blasi R; Di Caprio L; Fanci R; Garzia M; Martino B; Melillo L; Mitra ME; Nadali G; Nosari A; Picardi M; Potenza L; Salutari P; Trecarichi EM; Tumbarello M; Verga L; Vianelli N; Busca A;
Clin Infect Dis; 2012 Dec; 55(11):1515-21. PubMed ID: 22955439
[TBL] [Abstract][Full Text] [Related]
37. Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections.
Furuno JP; Tallman GB; Noble BN; Bubalo JS; Forrest GN; Lewis JS; Bienvenida AF; Holmes CA; Weber BR; McGregor JC
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012757
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
AbuTarif MA; Krishna G; Statkevich P
Curr Med Res Opin; 2010 Feb; 26(2):397-405. PubMed ID: 20001450
[TBL] [Abstract][Full Text] [Related]
39. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
40. Azole-based chemoprophylaxis of invasive fungal infections in paediatric patients with acute leukaemia: an internal audit.
Yunus S; Pieper S; Kolve H; Goletz G; Jürgens H; Groll AH
J Antimicrob Chemother; 2014 Mar; 69(3):815-20. PubMed ID: 24198097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
